Precision Biosciences Stock News

The European Medicines Agency accepts Amicus Therapeutics' (FOLD) MAA for AT-GAA, a potential treatment for Pompe disease.

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ASH21--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T

Post FDA approval, Merck's (MRK) anti-PD-1 therapy Keytruda is now approved as an adjuvant treatment for adult & pediatric patients with stage IIB, IIC or III melanoma following complete resection.

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector r

In last trading session, Precision BioSciences Inc. (NASDAQ:DTIL) saw 0.42 million shares changing hands with its beta currently measuring 0. Companys recent per share price level of $8.19 trading at -$0.53 or -6.08% at ring of the bell on the day assigns it a market valuation of $485.99M. That closing price of DTILs stock is Precision BioSciences Inc. Shares Rise 14.9% From The Lows But Will They Continue? Read More »

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T

The FDA grants Adagene (ADAG) a clearance to initiate clinical studies of its investigational candidate ADG116 in combination with pembrolizumab to treat advanced/metastatic solid tumors.

Novavax (NVAX) is likely to generate huge revenues as the company has started filing approvals for emergency use of its COVID-19 vaccine in multiple nations.

The European Commission grants marketing authorization to Gilead's (GILD) Trodelvy as a monotherapy for the second-line treatment of adults with metastatic triple-negative breast cancer.

The FDA grants a Regenerative Medicine Advanced Therapy designation to CRISPR Therapeutics' (CRSP) CTX110 targeting CD19+ B-cell malignancies.

Gilead (GILD) submits a biologics license application to the FDA for bulevirtide for the treatment of chronic hepatitis delta virus infection in adults with compensated liver disease.

Precision BioSciences, Inc. (NASDAQ:DTIL) has been assigned a consensus rating of Buy from the six ratings firms that are currently covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have covered the stock in the last year is $19.80. []

Shares of Precision BioSciences, Inc. (NASDAQ:DTIL) have been assigned a consensus rating of Buy from the six ratings firms that are currently covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have updated their coverage on the stock in the []

AbbVie (ABBV) secures approval in the EU for Skyrizi to treat adult patients with active psoriatic arthritis.

Novavax's (NVAX) secures approval for its COVID vaccine in the Philippines. The EMA begins reviewing the company's regulatory submission for its COVID vaccine. Evidently, the stock gains.